72 related articles for article (PubMed ID: 16239528)
1. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.
Kulik L; Laskowski J; Renner B; Woolaver R; Zhang L; Lyubchenko T; You Z; Thurman JM; Holers VM
J Immunol; 2019 Dec; 203(12):3136-3147. PubMed ID: 31732528
[TBL] [Abstract][Full Text] [Related]
2. Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.
Badar A; DeFreitas S; McDonnell JM; Yahya N; Thakor D; Razavi R; Smith R; Sacks S; Mullen GE
PLoS One; 2011 Apr; 6(4):e18275. PubMed ID: 21494666
[TBL] [Abstract][Full Text] [Related]
3. Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth.
Liang PH; Zhang KQ; Xu GL; Li YF; Wang LF; Nie ZL; Ye J; Wu G; Ge CG; Jin FS
Cancer Immunol Immunother; 2010 Jan; 59(1):93-101. PubMed ID: 19543726
[TBL] [Abstract][Full Text] [Related]
4. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2010 Aug; 285(35):27251-27258. PubMed ID: 20558730
[TBL] [Abstract][Full Text] [Related]
5. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
[TBL] [Abstract][Full Text] [Related]
6. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype.
Movsesyan N; Mkrtichyan M; Petrushina I; Ross TM; Cribbs DH; Agadjanyan MG; Ghochikyan A
J Neuroimmunol; 2008 Dec; 205(1-2):57-63. PubMed ID: 18838175
[TBL] [Abstract][Full Text] [Related]
7. The role of complement in the acquired immune response.
Nielsen CH; Fischer EM; Leslie RG
Immunology; 2000 May; 100(1):4-12. PubMed ID: 10809953
[TBL] [Abstract][Full Text] [Related]
8. C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement.
Liu F; Ryan ST; Fahnoe KC; Morgan JG; Cheung AE; Storek MJ; Best A; Chen HA; Locatelli M; Xu S; Schmidt E; Schmidt-Jiménez LF; Bieber K; Henderson JM; Lian CG; Verschoor A; Ludwig RJ; Benigni A; Remuzzi G; Salant DJ; Kalled SL; Thurman JM; Holers VM; Violette SM; Wawersik S
Mol Ther; 2024 Apr; 32(4):1061-1079. PubMed ID: 38382529
[TBL] [Abstract][Full Text] [Related]
9. The causal impact of complement C3d receptor 2 on head and neck cancer microenvironment and its implications for immunotherapy response prediction.
Ding Q; Xu W; Yang H; Wu W; Wu L; Chen X; Liu H; Qiu S
Heliyon; 2024 Apr; 10(7):e29312. PubMed ID: 38623210
[TBL] [Abstract][Full Text] [Related]
10. Fixing a Hole: Preventing Pneumococcal Pneumonia by Vaccination.
Rijkers GT
Front Immunol; 2016; 7():349. PubMed ID: 27679637
[No Abstract] [Full Text] [Related]
11. C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells.
De Groot AS; Ross TM; Levitz L; Messitt TJ; Tassone R; Boyle CM; Vincelli AJ; Moise L; Martin W; Knopf PM
Immunol Cell Biol; 2015 Feb; 93(2):189-97. PubMed ID: 25385064
[TBL] [Abstract][Full Text] [Related]
12. Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.
Zhang Z; Li Y; Xu S; Chen F; Zhang L; Jiang B; Chen X
Virol J; 2010 May; 7():89. PubMed ID: 20459691
[TBL] [Abstract][Full Text] [Related]
13. C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.
Toapanta FR; DeAlmeida DR; Dunn MD; Ross TM
Immunol Lett; 2010 Mar; 129(1):32-8. PubMed ID: 20064559
[TBL] [Abstract][Full Text] [Related]
14. Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide.
Mitsuyoshi JK; Hu Y; Test ST
Infect Immun; 2005 Nov; 73(11):7311-6. PubMed ID: 16239528
[TBL] [Abstract][Full Text] [Related]
15. Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.
Test ST; Mitsuyoshi JK; Hu Y
Infect Immun; 2005 Jan; 73(1):277-86. PubMed ID: 15618164
[TBL] [Abstract][Full Text] [Related]
16. Functional differences in IgG anti-polysaccharide antibodies elicited by immunization of mice with C3d versus ovalbumin conjugates of pneumococcal serotype 14 capsular polysaccharide.
Hu Y; Test ST
Vaccine; 2004 Nov; 23(1):21-8. PubMed ID: 15519703
[TBL] [Abstract][Full Text] [Related]
17. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.
Test ST; Mitsuyoshi J; Connolly CC; Lucas AH
Infect Immun; 2001 May; 69(5):3031-40. PubMed ID: 11292721
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.
Toapanta FR; Ross TM
Immunol Res; 2006; 36(1-3):197-210. PubMed ID: 17337780
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
